Lupin receives approval from U.S. FDA for Tenofovir Alafenamide Tablets

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tenofovir Alafenamide Tablets, 25 mg, a generic equivalent of Vemlidy® Tablets, 25 mg, of Gilead Sciences, Inc. This product will be manufactured at Lupin's Nagpur facility in India.

Tenofovir Alafenamide Tablets, 25 mg, (RLD Vemlidy®) had estimated annual sales of USD 531 million in the U.S. (IQVIA MAT December 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 652.45 as compared to the previous close of Rs. 644.20. The total number of shares traded during the day was 27593 in over 2330 trades.

The stock hit an intraday high of Rs. 658.50 and intraday low of 642.05. The net turnover during the day was Rs. 18006056.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA ANDA Approval TenofovirAlafenamideTablets